Cargando…

RNA biomarkers for alcohol use disorder

Alcohol use disorder (AUD) is highly prevalent and one of the leading causes of disability in the US and around the world. There are some molecular biomarkers of heavy alcohol use and liver damage which can suggest AUD, but these are lacking in sensitivity and specificity. AUD treatment involves psy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, Laura B., Mayfield, R. Dayne, Messing, Robert O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673015/
https://www.ncbi.nlm.nih.gov/pubmed/36407766
http://dx.doi.org/10.3389/fnmol.2022.1032362
_version_ 1784832863861997568
author Ferguson, Laura B.
Mayfield, R. Dayne
Messing, Robert O.
author_facet Ferguson, Laura B.
Mayfield, R. Dayne
Messing, Robert O.
author_sort Ferguson, Laura B.
collection PubMed
description Alcohol use disorder (AUD) is highly prevalent and one of the leading causes of disability in the US and around the world. There are some molecular biomarkers of heavy alcohol use and liver damage which can suggest AUD, but these are lacking in sensitivity and specificity. AUD treatment involves psychosocial interventions and medications for managing alcohol withdrawal, assisting in abstinence and reduced drinking (naltrexone, acamprosate, disulfiram, and some off-label medications), and treating comorbid psychiatric conditions (e.g., depression and anxiety). It has been suggested that various patient groups within the heterogeneous AUD population would respond more favorably to specific treatment approaches. For example, there is some evidence that so-called reward-drinkers respond better to naltrexone than acamprosate. However, there are currently no objective molecular markers to separate patients into optimal treatment groups or any markers of treatment response. Objective molecular biomarkers could aid in AUD diagnosis and patient stratification, which could personalize treatment and improve outcomes through more targeted interventions. Biomarkers of treatment response could also improve AUD management and treatment development. Systems biology considers complex diseases and emergent behaviors as the outcome of interactions and crosstalk between biomolecular networks. A systems approach that uses transcriptomic (or other -omic data, e.g., methylome, proteome, metabolome) can capture genetic and environmental factors associated with AUD and potentially provide sensitive, specific, and objective biomarkers to guide patient stratification, prognosis of treatment response or relapse, and predict optimal treatments. This Review describes and highlights state-of-the-art research on employing transcriptomic data and artificial intelligence (AI) methods to serve as molecular biomarkers with the goal of improving the clinical management of AUD. Considerations about future directions are also discussed.
format Online
Article
Text
id pubmed-9673015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96730152022-11-19 RNA biomarkers for alcohol use disorder Ferguson, Laura B. Mayfield, R. Dayne Messing, Robert O. Front Mol Neurosci Neuroscience Alcohol use disorder (AUD) is highly prevalent and one of the leading causes of disability in the US and around the world. There are some molecular biomarkers of heavy alcohol use and liver damage which can suggest AUD, but these are lacking in sensitivity and specificity. AUD treatment involves psychosocial interventions and medications for managing alcohol withdrawal, assisting in abstinence and reduced drinking (naltrexone, acamprosate, disulfiram, and some off-label medications), and treating comorbid psychiatric conditions (e.g., depression and anxiety). It has been suggested that various patient groups within the heterogeneous AUD population would respond more favorably to specific treatment approaches. For example, there is some evidence that so-called reward-drinkers respond better to naltrexone than acamprosate. However, there are currently no objective molecular markers to separate patients into optimal treatment groups or any markers of treatment response. Objective molecular biomarkers could aid in AUD diagnosis and patient stratification, which could personalize treatment and improve outcomes through more targeted interventions. Biomarkers of treatment response could also improve AUD management and treatment development. Systems biology considers complex diseases and emergent behaviors as the outcome of interactions and crosstalk between biomolecular networks. A systems approach that uses transcriptomic (or other -omic data, e.g., methylome, proteome, metabolome) can capture genetic and environmental factors associated with AUD and potentially provide sensitive, specific, and objective biomarkers to guide patient stratification, prognosis of treatment response or relapse, and predict optimal treatments. This Review describes and highlights state-of-the-art research on employing transcriptomic data and artificial intelligence (AI) methods to serve as molecular biomarkers with the goal of improving the clinical management of AUD. Considerations about future directions are also discussed. Frontiers Media S.A. 2022-11-04 /pmc/articles/PMC9673015/ /pubmed/36407766 http://dx.doi.org/10.3389/fnmol.2022.1032362 Text en Copyright © 2022 Ferguson, Mayfield and Messing. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Ferguson, Laura B.
Mayfield, R. Dayne
Messing, Robert O.
RNA biomarkers for alcohol use disorder
title RNA biomarkers for alcohol use disorder
title_full RNA biomarkers for alcohol use disorder
title_fullStr RNA biomarkers for alcohol use disorder
title_full_unstemmed RNA biomarkers for alcohol use disorder
title_short RNA biomarkers for alcohol use disorder
title_sort rna biomarkers for alcohol use disorder
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673015/
https://www.ncbi.nlm.nih.gov/pubmed/36407766
http://dx.doi.org/10.3389/fnmol.2022.1032362
work_keys_str_mv AT fergusonlaurab rnabiomarkersforalcoholusedisorder
AT mayfieldrdayne rnabiomarkersforalcoholusedisorder
AT messingroberto rnabiomarkersforalcoholusedisorder